News Reel
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
A New Bridge and Access That Helps Better Equip and Empower the Cholangiocarcinoma Patient's Capacity to More Effectively Respond
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]